Structure-based rational design enables efficient discovery of a new selective and potent AKT PROTAC degrader

被引:17
作者
Zhu, Cheng-Liang [2 ,4 ,7 ]
Luo, Xiaomin [1 ]
Tian, Tian [3 ]
Rao, Zijian [2 ]
Wang, Hanlin [10 ]
Zhou, Zhesheng [2 ]
Mi, Tian [5 ]
Chen, Danni [2 ]
Xu, Yongjin [9 ]
Wu, Yizhe
Che, Jinxin [3 ]
Zhou, Yubo [1 ,5 ,6 ]
Li, Jia [1 ,5 ,6 ]
Dong, Xiaowu [3 ,7 ,8 ]
机构
[1] Nanjing Univ Chinese Med, Sch Chinese Mat Med, Nanjing 210023, Peoples R China
[2] Zhejiang Univ, Inst Pharmacol & Toxicol, Coll Pharmaceut Sci, Zhejiang Prov Key Lab Anticanc Drug Res, Hangzhou 310058, Peoples R China
[3] Zhejiang Univ, Hangzhou Inst Innovat Med, Inst Drug Discovery & Design, Coll Pharmaceut Sci, Hangzhou 310058, Peoples R China
[4] Ctr Drug Safety Evaluat & Res ZJU, Hangzhou 310058, Peoples R China
[5] Chinese Acad Sci, Shanghai Inst Mat Med, Natl Ctr Drug Screening, State Key Lab Drug Res, Shanghai 201203, Peoples R China
[6] Chinese Acad Sci, Zhongshan Inst Drug Discovery, Shanghai Inst Mat Med, Zhongshan Tsuihang New Di 528400, Guangdon, Peoples R China
[7] Zhejiang Univ, Innovat Inst Artificial Intelligence Med, Hangzhou 310016, Peoples R China
[8] Zhejiang Univ, Canc Ctr, Hangzhou 310058, Peoples R China
[9] Canc Hosp Univ Chinese Acad Sci, Chinese Acad Sci, Zhejiang Canc Hosp, Inst Basic Med & Canc, Hangzhou 310005, Peoples R China
[10] Fudan Univ, Sch Pharm, Shanghai 200032, Peoples R China
基金
中国国家自然科学基金;
关键词
AKT; Protein kinase B; PROTAC; Chemical degrader; Rational design; MANTLE CELL LYMPHOMA; BIOLOGICAL EVALUATION; PATHWAY; DEGRADATION; INHIBITION; DERIVATIVES; BTK; IBRUTINIB; MK-2206; TARGET;
D O I
10.1016/j.ejmech.2022.114459
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
AKT and associated signaling pathways have been recognized as promising therapeutic targets for decades, and growing evidence indicates that inhibition or degradation of cellular AKT are viable strategies to treat cancer. Guided by an in silico modeling approach for rational linker design and based on our previous work in this field, we herein efficiently synthesized a small group of cereblon-recruiting AKT PROTAC molecules and identified a highly potent AKT degrader B4. Compared to the existing AKT degraders, B4 has a structurally unique AKT targeting warhead derived from the pyrazole-furan conjugated piperidine derivatives. It induces selective degradation of all three isoforms of AKT and exhibits efficacious anti-proliferation against several human hematological cancers. Notably, B4 demonstrates potent inhibition of AKT downstream signaling superior to its parental inhibitor. Together with its active analogs, B4 expands the arsenal of AKT chemical degraders as a valuable probe to uncover AKTs new functions and as a potential drug candidate to treat cancer.
引用
收藏
页数:15
相关论文
共 71 条
  • [41] AKT/PKB Signaling: Navigating the Network
    Manning, Brendan D.
    Toker, Alex
    [J]. CELL, 2017, 169 (03) : 381 - 405
  • [42] AKT Inhibitors: New Weapons in the Fight Against Breast Cancer?
    Martorana, Federica
    Motta, Gianmarco
    Pavone, Giuliana
    Motta, Lucia
    Stella, Stefania
    Vitale, Silvia Rita
    Manzella, Livia
    Vigneri, Paolo
    [J]. FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [43] Inhibition of Akt with small molecules and biologics: historical perspective and current status of the patent landscape
    Mattmann, Margrith E.
    Stoops, Sydney L.
    Lindsley, Craig W.
    [J]. EXPERT OPINION ON THERAPEUTIC PATENTS, 2011, 21 (09) : 1309 - 1338
  • [44] The PI3K/AKT Pathway as a Target for Cancer Treatment
    Mayer, Ingrid A.
    Arteaga, Carlos L.
    [J]. ANNUAL REVIEW OF MEDICINE, VOL 67, 2016, 67 : 11 - 28
  • [45] PROTACs: An Emerging Therapeutic Modality in Precision Medicine
    Nalawansha, Dhanusha A.
    Crews, Craig M.
    [J]. CELL CHEMICAL BIOLOGY, 2020, 27 (08): : 998 - 1014
  • [46] The Akt pathway in oncology therapy and beyond (Review)
    Nitulescu, George Mihai
    Van De Venter, Maryna
    Nitulescu, Georgiana
    Ungurianu, Anca
    Juzenas, Petras
    Peng, Qian
    Olaru, Octavian Tudorel
    Gradinaru, Daniela
    Tsatsakis, Aristides
    Tsoukalas, Dimitris
    Spandidos, Demetrios A.
    Margina, Denisa
    [J]. INTERNATIONAL JOURNAL OF ONCOLOGY, 2018, 53 (06) : 2319 - 2331
  • [47] Akt inhibitors in cancer treatment: The long journey from drug discovery to clinical use
    Nitulescu, George Mihai
    Margina, Denisa
    Juzenas, Petras
    Peng, Qian
    Olaru, Octavian Tudorel
    Saloustros, Emanouil
    Fenga, Concetina
    Spandidos, Demetrios A.
    Libra, Masimo
    Tsatsakis, Aristidis M.
    [J]. INTERNATIONAL JOURNAL OF ONCOLOGY, 2016, 48 (03) : 869 - 885
  • [48] Plasticity in binding confers selectivity in ligand-induced protein degradation
    Nowak, Radoslaw P.
    DeAngelo, Stephen L.
    Buckley, Dennis
    He, Zhixiang
    Donovan, Katherine A.
    An, Jian
    Safaee, Nozhat
    Jedrychowski, Mark P.
    Ponthier, Charles M.
    Ishoey, Mette
    Zhang, Tinghu
    Mancias, Joseph D.
    Gray, Nathanael S.
    Bradner, James E.
    Fischer, Eric S.
    [J]. NATURE CHEMICAL BIOLOGY, 2018, 14 (07) : 706 - +
  • [49] Targeted protein degradation: elements of PROTAC design
    Paiva, Stacey-Lynn
    Crews, Craig M.
    [J]. CURRENT OPINION IN CHEMICAL BIOLOGY, 2019, 50 : 111 - 119
  • [50] Protein Interaction Z Score Assessment (PIZSA): an empirical scoring scheme for evaluation of protein-protein interactions
    Roy, Ankit A.
    Dhawanjewar, Abhilesh S.
    Sharma, Parichit
    Singh, Gulzar
    Madhusudhan, M. S.
    [J]. NUCLEIC ACIDS RESEARCH, 2019, 47 (W1) : W331 - W337